Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for HOPE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for HOPE and 80,000+ other tickers.
See exactly how HOPE's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HOPE and 80,000+ other tickers.
Hope Bancorp, Inc., established in 2000 and headquartered in Los Angeles, California, functions as the parent entity for Bank of Hope. Through its subsidiary, Bank of Hope, it delivers a comprehensive suite of banking solutions to both individuals and small to medium-sized enterprises across the United States. Customers have access to a wide array of deposit accounts, encompassing personal and business checking, money market accounts, savings accounts, certificate of deposits, and individual retirement accounts. The institution's lending portfolio is extensive, covering various financial…
Hope Bancorp is rated Buy, trading below book value and at a 43% discount to the financial sector despite a forward ROE 5.6x higher than the sector median. The MANUBANK acquisition is expected to drive near-term earnings growth, with management guiding for 20% loan and 15–20% revenue growth in FY26. NIM expansion, robust CET1 ratio (12.3%), and stable asset quality support a 4.2% yield and ongoing share repurchases.
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (“the Company”) (NASDAQ: HOPE) today announced that the Company will report financial results for its third quarter and nine months ended September 30, 2026, before the markets open on Wednesday, October 28, 2026. A conference call to discuss financial results for the third quarter and nine months ended September 30, 2026, will be held on Wednesday, October 28, 2026, at 9:30 a.m. Pacific Time / 12:30 p.m. Eastern Time. A presentation deck to acco.
Hope Bancorp (HOPE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Hope Bancorp, Inc. (NASDAQ: HOPE - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $13.06 and traded as high as $13.75. Hope Bancorp shares last traded at $13.57, with a volume of 1,048,202 shares traded. Wall Street Analyst Weigh In Several
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).